... Abstract Aspirin exacerbated respiratory disease (AERD) has been defined as a non-steroidal anti-inflammatory drug (NSAID)-triggered hypersensitivity, non-allergic bronchial asthma and chronic rhinosinusitis (CRS) with nasal polyps. The underlying pathophysiology of AERD is not completely...

... concerning the pathogenesis of these reactions and the availability of novel in vitro diagnostic methods sparing both patient and physician of the risks inherent to in vivo provocation tests. Aspirin is one of the most widely used drugs in the world and hypersensitivity reactions to aspirin and non...

...-inflammatory drugs (NSAIDs) including aspirin have been widely reported. The development of cyclooxygenase (COX)-2 inhibitors with the potential of minimizing GI toxic effects was welcomed by many clinicians. However, after reports of cardiovascular hazards related to COX-2 inhibitors, the trend...

... Abstract Platelets play a critical role in the pathophysiology of acute coronary syndrome and thromboembolic complications associated with atrial fibrillation. Despite the development of newer and more potent antiplatelet agents, aspirin remains the cornerstone of antithrombotic therapy...

... Abstract Although antithrombotic therapy plays a central role in the treatment of cardiac disorders and peripheral arterial diseases, recent studies suggest that the risk of upper gastrointestinal bleeding is increased by the concomitant use of anti-platelet drugs with low-dose aspirin. We set...

... Abstract In about 10% of adult asthmatics and 20-40% of patientswith chronic idiopathic urticaria, aspirin can precipitate oraggravate symptoms of the disease. These hypersensitivityreactions are the markers of two distinct clinical syndromes,which develop according to a characteristic pattern...

... to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177-180. 3. Samter M, Beers RF Jr: Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-983. 4. Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kiełbasa B: Aspirin...

... of bleeding events and have an efficacy no better than that of aspirin. Therefore, anticoagulants are not widely used unless patients develop recurrent ischemic symptoms despite receiving antiplatelet therapy. Because ICAS progression is not uncommon and the risk of stroke recurrence is high when aspirin...

...References References 1. Hirschberg SR: Mitteilung über einen Fall von Nebenwirkung des Aspirin. Dtsch Med Wochenschr 1902;28:416. 2. Gilbert GB: Unusual idiosyncrasy to aspirin. J Am Med Assoc 1911;56:1262. 3. Widal MF, Abrami P, Lermoyez J: Anaphylaxie et idiosyncrasie. Presse Med...

...References References 1. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-632 2. Burch JW, Stanford N, Majerus PW: Inhibition of platelet prostaglandin synthase by oral aspirin. J...

... Abstract Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are often incriminated in hypersensitivity reactions leading to anaphylaxis. Two populations are at the high risk of developing such reactions: patients with asthma and those with urticaria. In a subset of asthmatics...

... predominantly in use are aspirin, clopidogrel, and combination regimens. Novel antiplatelet agents either in use or in advance clinical development seek an indication in the management of stroke patients; yet data are limited. The present review focuses on the optimization of antithrombotic therapy in the field...

..., but it is not excluded that lipid-lowering agents and/or antihypertensive drugs are also important. For current guidelines, monotherapy of antiplatelet agent remains the gold standard in emergency. However, most recent data and meta-analysis support a combination therapy of clopidogrel and aspirin. Data on treatment...

... of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010;160:380-386. 7. UK-TIA Study Group: The United Kingdom Transient Ischaemic Attack (UK...

... Abstract Historically, studies of antithrombotic therapy in ischemic cerebrovascular disease have included both stroke and transient ischemic attack (TIA). Thus, therapy regimes are very similar. Aspirin (75-325 mg within 48 h after onset of symptoms) is still the standard antithrombotic...